A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Keller, Jesse [1 ]
Fiala, Mark A. [1 ]
Sekhar, Jeevan [2 ]
Ceriotti, Connie [1 ]
Allen, Melissa [1 ]
Abboud, Camille N. [1 ]
Stockerl-Goldstein, Keith E. [1 ]
Wildes, Tanya M. [1 ]
Tomasson, Michael H. [1 ]
Vij, Ravi [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Reid Hosp, Richmond, IN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients
    Romano, Alessandra
    Chiarenza, Annalisa
    Conticello, Concetta
    Cavalli, Maide
    Vetro, Calogero
    Di Raimondo, Cosimo
    Cunsolo, Rosario
    Palumbo, Giuseppe Alberto
    Di Raimondo, Francesco
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2014, 93 (03) : 207 - 213
  • [42] A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma
    Watanabe, Takashi
    Tobinai, Kensei
    Matsumoto, Morio
    Suzuki, Kenshi
    Sunami, Kazutaka
    Ishida, Tadao
    Ando, Kiyoshi
    Chou, Takaaki
    Ozaki, Shuji
    Taniwaki, Masafumi
    Uike, Naokuni
    Shibayama, Hirohiko
    Hatake, Kiyohiko
    Izutsu, Koji
    Ishikawa, Takayuki
    Shumiya, Yoshihisa
    Kashihara, Tomohisa
    Iida, Shinsuke
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 172 (05) : 745 - 756
  • [43] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Gabriel N. Waterman
    Ori Yellin
    Regina A. Swift
    Russell Mapes
    Benjamin Eades
    Emily Ackerman
    James R. Berenson
    Annals of Hematology, 2011, 90 : 193 - 200
  • [44] Weekly Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone Is a Safe and Effective Therapy for Elderly Patients With Relapsed/Refractory Multiple Myeloma
    Gozzetti, Alessandro
    Fabbri, Alberto
    Oliva, Stefania
    Marchini, Elena
    Bocchia, Monica
    Defina, Marzia
    Lauria, Francesco
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (01): : 68 - 72
  • [45] Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
    Blade, Joan
    Sonneveld, Pieter
    Miguel, Jesus E. San
    Sutherland, Heather J.
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Robak, Tadeusz
    Cibeira, M. Teresa
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (06): : 352 - 355
  • [46] A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
    Waterman, Gabriel N.
    Yellin, Ori
    Swift, Regina A.
    Mapes, Russell
    Eades, Benjamin
    Ackerman, Emily
    Berenson, James R.
    ANNALS OF HEMATOLOGY, 2011, 90 (02) : 193 - 200
  • [47] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    Blood Cancer Journal, 9
  • [48] Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency
    Badros, A. Z.
    Vij, R.
    Martin, T.
    Zonder, J. A.
    Wong, A. F.
    Woo, T.
    Boussina, K.
    Wang, Z.
    Niesvizky, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [50] A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
    Andrea Wang-Gillam
    Nilay Thakkar
    A. Craig Lockhart
    Kerry Williams
    Maria Baggstrom
    Michael Naughton
    Rama Suresh
    Cynthia Ma
    Benjamin Tan
    Wooin Lee
    Xuntian Jiang
    Tibu Mwandoro
    Lauren Trull
    Stefanie Belanger
    Allison N. Creekmore
    Feng Gao
    Paula M. Fracasso
    Joel Picus
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 419 - 426
12345